Tools   Select Another Resource Report Type

http://www.utsouthwestern.edu/research/core-facilities/obrien-kidney/core-services/animal-core.html

Core that generates and distributes several kidney-specific Cre recombinase and tetracycline-inducible activator and repressor lines to be crossed to floxed or tet responder lines provided by co-investigators.

Proper citation: George M. O'Brien Kidney Research Core Center - UT Southwestern Medical Center Animal Models Core (RRID:SCR_015292) Copy   

•   Source: SciCrunch Registry

https://www.pkd-rrc.org

Consortium develops and shares investigative resources, reagents and expertise with broader research community to accelerate innovation and discovery in field of polycystic kidney disease.Provides assistance with protocols and trouble shooting. Provides funding opportunities.

Proper citation: Polycystic Kidney Disease Research Resource Consortium (RRID:SCR_022033) Copy   

•   Source: SciCrunch Registry

http://www.baltimorepkdcenter.org/mouse/index.shtml

Core facility which provides mouse models and a biobank of tissues and other materials for research.

Proper citation: Baltimore Polycystic Kidney Disease (PKD) Research and Clinical Core Center Mouse Models and Biobank (RRID:SCR_015319) Copy   

•   Source: SciCrunch Registry

http://www.mayo.edu/research/centers-programs/molecular-genetics-proteomics-core/overview

Core services include mutation screening of cell lines derived from ADPKD patients, mutation screening of large, typical ADPKD populations, genetic screening of atypical PKD families, cystic Kidney and Liver Disease Biobank (CKLBB) from ADPKD patients, and urine collection and fractionation.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester Molecular Genetics and Biomarker Core (RRID:SCR_015308) Copy   

•   Source: SciCrunch Registry

http://www.baltimorepkdcenter.org/cell/index.shtml

Core faiclity that provides researchers with cell culturing and engineering services.

Proper citation: Baltimore Polycystic Kidney Disease (PKD) Research and Clinical Core Center Cell Culture and Engineering (RRID:SCR_015323) Copy   

•   Source: SciCrunch Registry

https://www.uab.edu/medicine/obriencenter/cores/bioanalytical-core

Core that provides bioenergetics, oxidative stress analysis and metabolite analysis support for AKI research. It includes protocols and technology for bioanalytical analysis of oxidative stress and cellular bioenergetics as well as post-translational modifications.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Bioanalytical Core (RRID:SCR_015280) Copy   

•   Source: SciCrunch Registry

https://www.uab.edu/medicine/obriencenter/cores/pre-clinical-studies-of-aki

Core that provides services such as expertise in development and training in the use of rodent models of AKI, specifically in the setting of ischemia/reperfusion (I/R) injury, sepsis and renal transplantation, gamma-ray imaging (gamma camera, microSPECT/CT, microPET/CT), metabolic assessments of kidney O2 consumption, and technical expertise in isolation of primary renal and vascular cell in culture.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Pre-Clinical Studies of AKI (RRID:SCR_015278) Copy   

•   Source: SciCrunch Registry

https://www.uab.edu/medicine/obriencenter/center-overview/administration

Core facility which coordinates the various activities of the center. Its various duties include facilitating interactions and collaboration among the researchers of the center, promoting scientific development through education and Pilot funding, organizing and supporting seminars, journal clubs and symposia, and maintaining communication with members.

Proper citation: UAB-UCSD Core Center for Acute Kidney Injury Research Administrative Core (RRID:SCR_015279) Copy   

•   Source: SciCrunch Registry

http://www.mayo.edu/research/centers-programs/model-systems-core/overview

Core that makes available PKD model systems and technologies to PKD researchers at Mayo and at other institutions. Its services include C. elegans PKD-targeted services, Zebrafish PKD-targeted services, and Rodent PKD-targeted services.

Proper citation: Translational Polycystic Kidney Disease (PKD) Center at Mayo Clinic Rochester Model Systems Core (RRID:SCR_015312) Copy   

•   Source: SciCrunch Registry

http://archives.niddk.nih.gov/patient/aask/aask.aspx

Clinical trial investigating whether a specific class of antihypertensive drugs (beta-adrenergic blockers, calcium channel blockers, or angiotensin converting enzyme inhibitors) and/or the level of blood pressure would influence progression of hypertensive kidney disease in African Americans. The initiative consisting of 21 clinical centers and a data-coordinating center is followed by a Continuation of AASK Cohort Study to investigate the environmental, socio-economic, genetic, physiologic, and other co-morbid factors that influence progression of kidney disease in a well-characterized cohort of African Americans with hypertensive kidney disease. Only patients who were previously in the randomized trial are eligible for the cohort study. A significant discovery was made in the treatment strategy for slowing kidney disease caused by hypertension. Angiotensin-converting enzyme (ACE) inhibitors, compared with calcium channel blockers, were found to slow kidney disease progression by 36 percent, and they drastically reduced the risk of kidney failure by 48 percent in patients who had at least one gram of protein in the urine, a sign of kidney failure. ACE inhibitors have been the preferred treatment for hypertension caused by diabetes since 1994; however, calcium channel blockers have been particularly effective in controlling blood pressure in African Americans. The AASK study now recommends ACE inhibitors to protect the kidneys from the damaging effects of hypertension. The Continuation of AASK Cohort Study will be followed at the clinical centers. The patients will be provided with the usual clinical care given to all such patients at the respective centers. Baseline demographic information, selected laboratory tests, and other studies are being obtained at the initiation of the Continuation Study. The patients will be seen quarterly at the centers, and some selected studies done at these visits. Samples will be obtained and stored for additional studies and analyses at a later date.

Proper citation: AASK Clinical Trial and Cohort Study (RRID:SCR_006985) Copy   

•   Source: SciCrunch Registry

http://rgd.mcw.edu/rgdCuration/?module=portal&func=show&name=renal

An integrated resource for information on genes, QTLs and strains associated with a variety of kidney and renal system conditions such as Renal Hypertension, Polycystic Kidney Disease and Renal Insufficiency, as well as Kidney Neoplasms.

Proper citation: Renal Disease Portal (RRID:SCR_009030) Copy   

•   Source: SciCrunch Registry

https://www.cincinnatichildrens.org/research/divisions/n/nephrology/center-of-excellence

Center whose goal is to support basic, translational, and clinical research on critical pediatric kidney diseases by focusing on Acute Kidney Injury, Nephrotic Syndrome, and Lupus Nephritis.

Proper citation: Pediatric Centers of Excellence in Nephrology at Cincinnati Children's Hospital Medical Center (RRID:SCR_015302) Copy   

•   Source: SciCrunch Registry

http://www.perl-study.org

PERL is a clinical trial for people with type 1 diabetes who have early signs of kidney problems. Its goal is to test a new way to reduce loss of kidney function using a safe and inexpensive medicine.

Proper citation: Preventing Early Renal Loss in Diabetes (PERL) (RRID:SCR_015862) Copy   

•   Source: SciCrunch Registry

http://clinicaltrials.gov/show/NCT00271999

Randomized controlled clinical trial where subjects will be randomized to conventional hemodialysis delivered three days per week home arm or to the six times per week nocturnal home hemodialysis arm which will follow any dialysis prescription provided their prescribed standardized Kt/V is at least 4.0 and treatment time is at least 6.0 hours, six times per week. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 12 months. Primary Outcome Measures: * composite of 12 month mortality and the change over 12 months in left ventricular mass by cine-MRI, * a composite of 12 month mortality and the change over 12 months in the SF-36 RAND physical health composite Secondary Outcome Measures: * cardiovascular structure/funct (change in LV mass over 12 mos), health-related QoL/phys funct (change over 12 mos in PHC), * depression / dis burden (change over 12 mos in Beck Depression Inv.), nutrition (change over 12 mos in serum albumin, cognitive funct (change over 12 mos in TrailMaking Test B), mineral metabolism (change over 12 mos in aveg pre-dialysis serum phosphorus), * clin events (rate of non-access hospital or death * hypertension, anemia

Proper citation: Frequent Hemodialysis Network Nocturnal Trial (RRID:SCR_007014) Copy   

•   Source: SciCrunch Registry

https://clinicaltrials.gov/study/NCT01885559

Consortium established to design and implement clinical trials of treatments that might slow the progressive loss of renal function in Polycystic Kidney Disease (PKD). Two multicenter randomized, double-blind, placebo controlled clinical trials are running concurrently to study the efficacy of renin-angiotensin-aldosterone system blockade on the progression of cystic disease (kidney volume) and on the decline in renal function in autosomal dominant polycystic kidney disease (ADPKD). Study A is to study whether intensive ACE-I/ARB blockade decrease the progression of cystic disease compared to ACE-I monotherapy patients with early disease, relatively preserved renal function, and high-normal BP or hypertension. Study B is to study whether intensive ACE-I/ARB blockade as compared to ACE-I monotherapy slow the decline in kidney function, end-stage of renal disease, or death in the setting of standard blood pressure control in hypertensive patients with moderately advanced disease.

Proper citation: HALT PKD (RRID:SCR_001529) Copy   

•   Source: SciCrunch Registry

http://medicine.iupui.edu/neph/obrien/probe

Core facility which develops and characterizes methods for expressing fluorescent biosensors in the rodent kidney to be paried with intravital microscopy.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis Probe Delivery Core (RRID:SCR_015274) Copy   

•   Source: SciCrunch Registry

http://www.uab.edu/medicine/hrfdcc/

Center that focuses on understanding the causes of Cystic Kidney Disease and other related disorder and the development of new therapeutic strategies.

Proper citation: UAB Hepatorenal Fibrocystic Diseases Core Center (RRID:SCR_015311) Copy   

•   Source: SciCrunch Registry

https://repository.niddk.nih.gov/study/44

Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes.

Proper citation: Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) Copy   

•   Source: SciCrunch Registry

http://medicine.iupui.edu/neph/obrien/

Imaging center which provides renal and urological researchers access to intravital optical microscopy and 3-dimensional quantitative digital image analysis.

Proper citation: Indiana O'Brien Center for Advanced Microscopic Analysis (RRID:SCR_015271) Copy   

•   Source: SciCrunch Registry

https://research.med.virginia.edu/pcen/

Center for the study of the development of the kidney during embryonic, fetal and postnatal life. As a collaboration between the University of Virginia and Tulane University, they use an interdisciplinary and inter-institutional approach for their research.

Proper citation: Pediatric Centers of Excellence in Nephrology at University of Virginia (RRID:SCR_015307) Copy   

•   Source: SciCrunch Registry